Background. Prediction of survival in patients diagnosed with lung cancer remains problematical.The aim of the present study was\nto examine the clinical utility of an established objective marker of the systemic inflammatory response, the Glasgow Prognostic\nScore, as the basis of risk stratification in patients with lung cancer. Methods. Between 2005 and 2008 all newly diagnosed lung\ncancer patients coming through the multidisciplinary meetings (MDTs) of four Scottish centres were included in the study. The\ndetails of 882 patients with a confirmed new diagnosis of any subtype or stage of lung cancer were collected prospectively. Results.\nThe median survival was 5.6 months (IQR 4.8ââ?¬â??6.5). Survival analysis was undertaken in three separate groups based on mGPS\nscore. In the mGPS 0 group the most highly predictive factors were performance status, weight loss, stage of NSCLC, and palliative\ntreatment offered. In the mGPS 1 group performance status, stage of NSCLC, and radical treatment offered were significant. In\nthe mGPS 2 group only performance status and weight loss were statistically significant. Discussion. This present study confirms\nprevious work supporting the use of mGPS in predicting cancer survival; however, it goes further by showing how it might be used\nto provide more objective risk stratification in patients diagnosed with lung cancer.
Loading....